Sun | Mar 26, 2017

$1,000 Sovaldi now hepatitis treatment of choice

Published:Wednesday | July 30, 2014 | 7:00 AM
This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi. The $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice. - AP PHOTOS

WASHINGTON (AP):

A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than three million.

Even with insurers reluctant to pay, Sovaldi prescriptions have eclipsed those for all other hepatitis C pills combined in a matter of months, new data from IMS Health indicate. The promise of a real cure, with fewer nasty side effects, has prompted thousands to get treated.

But clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or 56 per cent.

Two senators have unearthed documents that suggest the initial developers of Sovaldi considered pricing it at less than half as much. The health-insurance industry is publicly scolding Gilead, and state health-care programmes are pushing back.

The repercussions go beyond one drug and one disease. A number of promising cancer medications near approval could be drawn into the storm over costs.

"You can't put too fine a point on the sort of moral dilemma that we have here," said Michael Kleinrock, director of the IMS Institute, which studies prescription-drug trends. "This is something that the research-based pharmaceutical industry reaches for all the time: a cure. But when they achieve one, can we afford it?"

New data from IMS Health, the parent company of the institute, illustrate Sovaldi's impact since its December debut:

The number of pharmacy prescriptions for all hepatitis C pills has soared, highlighting demand. In May, more than 48,000 prescriptions were filled for four such medications, with Sovaldi accounting for three-fourths of the total. Compare that to prescriptions for May 2013, before Sovaldi became available, which totaled about 6,200.

In Sovaldi's first 30 weeks on the market, 62,000 new patients tried the drug, nearly three times as many as had tried an earlier medication that showed promise. That makes Sovaldi the most successful launch for any hepatitis C drug. Gilead expects to have a successor soon that will make treatment easier to tolerate, because it won't require patients to take companion medications with strong side effects.